BMS expands CAR-T portfolio with $1.5bn Orbital buyout
BMS, which already has two FDA-approved CAR T-cell therapies, is eyeing entry into the growing in vivo market.
Cytiva Navigating cell therapy WP 4
Rocket ditches blood disorder gene therapy in ongoing pipeline pivot
Takeda walks away from cell therapy in priority U-turn
The Baltics: a region punching above its weight on the global life sciences stage
European PE company prioritising CGT and other novel modality investments
UniQure stock surges 247% after mid-stage Huntington’s win
Imunon’s Phase III-stage IL-12 gene therapy alters tumour microenvironment in ovarian cancer
Bluebird bio flies to pastures new with Genetix rebranding
